#EMBER3

OncoDaily

@oncodaily.bsky.social

10 months ago

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - OncoDaily ESMO Breast 2025: Imlunestrant + abemaciclib shows PFS benefit in CDK4/6i-pretreated ER+/HER2- advanced breast cancer, per EMBER-3 data.

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib

The ASCO Post

@ascopost.bsky.social

11 months ago

🚨 New from #SABCS2024: Dr. Komal Jhaveri presents Phase III #EMBER3 trial results!

Imlunestrant, both as monotherapy & combo with Abemaciclib, shows improved PFS in ER+/HER2- advanced breast cancer.
#oncology #breastcancer #clinicaltrials ascopost.com/videos/2024-...

Sana Al Sukhun

@sanaalsukhun.bsky.social

1 year ago

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...

Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs

www.nejm.org/doi/full/10....

Lorenzo Gerratana

@gerratana.bsky.social

1 year ago

#EMBER3 takeaways:

imlunestrant 🔼 PFS in patients with #ESR1 mut #MBC (5.5 vs. 3.8 mo)

Combination with abemaciclib further 🔼 PFS regardless of ESR1 and PIK3CA #ctDNA status (9.4 vs. 5.5 mo)

Previous CDK4/6i were mainly Palbo and Ribo in the MBC setting

#SABCS24 #bcsm #BreastCancer

Dana-Farber’s Breast Oncology Center

@dfcibreastonc.bsky.social

1 year ago

Dr. Harold Burstein discussed the #EMBER3 study data in the #SABCS24 General Session 1.

Margaret Gatti-Mays, MD MPH

@drgattimays.bsky.social

1 year ago

#EMBER3 Continued … side effect profile with diarrhea, fatigue, nausea but most low grade. Also acknowledged was injection site pain/reaction from SOc - fulvestrant (commonly minimalists). Imlunestrant + abema therapy looks promising - may be another oral combination for patients with mBC

Margaret Gatti-Mays, MD MPH

@drgattimays.bsky.social

1 year ago

#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm

Erika Hamilton MD, FASCO

@erikahamilton9.bsky.social

1 year ago

#EMBER3

Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut

However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1

* note prior CDK not required

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

< 2 weeks to #SABCS24, here is a📝 of🔑abstracts from #CommunityOncologists perspective.

- #EUROPA
- #EMBER3
- #SONIA
- #PADMA
- #TOUCH
- #DB012
- #OlympiA
- #KN522
- #REDUSE

#MedEd #bcsm #OncSky #breastcancer #MedSky @dr-rshatsky.bsky.social @drgattimays.bsky.social @hoperugo.bsky.social